Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Curis, Inc.
Mayo Clinic
Miltenyi Biomedicine GmbH
Incyte Corporation
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Amgen
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Nantes University Hospital
University of Rochester
M.D. Anderson Cancer Center
University of Washington
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Northside Hospital, Inc.
Institute of Hematology & Blood Diseases Hospital, China
Dren Bio
West Virginia University
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
BeOne Medicines
Roswell Park Cancer Institute
National Cancer Institute (NCI)
Miltenyi Biomedicine GmbH
Nantes University Hospital
Ruijin Hospital
The University of Queensland
AstraZeneca
BeOne Medicines
University of Miami
M.D. Anderson Cancer Center
BeOne Medicines
Wake Forest University Health Sciences
National Institutes of Health Clinical Center (CC)
University of Washington
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Institute of Hematology & Blood Diseases Hospital, China
Masonic Cancer Center, University of Minnesota
National Institutes of Health Clinical Center (CC)
Quetzal Therapeutics
Technical University of Munich
National Institutes of Health Clinical Center (CC)
Kousai Bio Co., Ltd.